7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans
Key Takeaways
- MMR and varicella are considered no earlier than 24 months only when immunocompetent, without active GVHD, off immunosuppression, and after checking vaccine-specific antibody-product intervals and contraindications.
- Close contacts should receive routine vaccines; use specific precautions for LAIV in a protected environment, rotavirus stool shedding, a post-varicella-vaccine rash, and OPV received outside the United States.
- Vaccinating household contacts protects the recipient through cocooning, so household vaccination status is part of the transplant infection-prevention plan rather than an unrelated primary-care matter.
- A survivorship plan is created before transition and updated over time; it summarizes transplant exposures, complications, medicines, vaccines, surveillance, urgent symptoms and ownership across clinicians.
1. Live Attenuated Vaccines: Criteria, Schedules & Strict Safety Rules
Live attenuated vaccines—specifically Measles, Mumps, Rubella (MMR) and Varicella (VAR)—contain replication-competent viral strains. In severely immunocompromised hosts, these attenuated strains can escape immune clearance, causing fatal disseminated viral infection, vaccine-strain encephalitis, or pneumonitis.
Live-vaccine gate All of the following must be satisfied under current national and transplant-program guidance:
- At least 24 months have elapsed since HCT.
- The patient is immunocompetent, with no active GVHD.
- The patient is off immunosuppressive therapy.
- Product-specific contraindications and timing after antibody-containing products such as IVIG have been checked.
Serology or lymphocyte measurements may inform selected decisions but are not substitutes for the complete clinical gate, and CDC does not publish a universal “off every agent for 8–12 months” rule.
Live Vaccine Protocols (When Eligible) & Key Contraindications
- MMR Vaccine: Administer a 2-dose series separated by at least 4 weeks.
- Varicella vaccine: If eligible and indicated, patients age 13 years or older receive 2 doses separated by at least 4 weeks; also observe the required interval after IVIG or other antibody-containing products.
- Other live products: Do not give OPV to the recipient. LAIV, oral typhoid, yellow fever, BCG, and other live products require the applicable immune-competence, travel, and specialist guidance; they are not interchangeable with the MMR/varicella pathway.
2. Household Contact and Vaccine Precautions
Household members should generally receive routine age-appropriate vaccines because preventing wild-type infection protects the HCT recipient. Apply these practical precautions:
- Influenza: Inactivated influenza vaccine is preferred for close contacts of a severely immunocompromised patient in a protected environment. If a contact receives LAIV, follow current CDC separation precautions for that special setting.
- MMR and varicella: Routine vaccination of susceptible contacts is encouraged. If a varicella vaccine recipient develops a rash, avoid direct contact with the HCT recipient until the rash resolves.
- Rotavirus: Infants in the home should receive routine rotavirus vaccine. Everyone should use meticulous hand hygiene after diaper changes because vaccine virus may shed in stool; the HCT recipient need not be categorically removed from all diaper care unless the clinical team advises it.
- Oral polio: OPV is not used routinely in the United States. If a household member receives OPV elsewhere, contact the transplant/infectious-disease team for shedding precautions; use IPV when an alternative is available.
The nurse checks the current CDC guidance, the recipient's immune status, and the actual product rather than labeling every live vaccine an equal household hazard.
3. Survivorship Care Plan
Create the plan before care becomes fragmented and update it after major transitions, new GVHD therapy, relapse or late effect. Include diagnosis/disease status; conditioning and cumulative radiation exposure; graft source, donor and HLA context; major HCT complications; current GVHD organs and immunosuppression; prophylaxis and allergies; vaccine doses/deferrals; fertility/sexual-health issues; psychosocial and financial needs; and emergency contact instructions.
For every surveillance task, identify the responsible clinician, timing, result location and trigger for transplant-team reconsultation. Share the plan with the patient, chosen caregiver/support people and primary/specialty clinicians with permission. It is an active coordination tool, not proof that a fixed 6–12-month handoff is safe for every recipient.
4. Antibody Products, B-Cell-Depleting Therapy and Deferral Intervals
Two exposures routinely make an otherwise eligible patient temporarily ineligible, and both are easy to miss because they appear on the medication list rather than the vaccine record.
Antibody-containing products. Immune globulin and other antibody-containing products contain passively acquired measles and varicella antibody that neutralizes live vaccine virus and blunts the immune response. ACIP publishes product- and dose-specific deferral intervals before MMR or varicella vaccination, which lengthen as the immunoglobulin dose increases; standard replacement dosing and high-dose regimens carry different waiting periods. Look the interval up against the actual product and dose the patient received rather than applying one remembered number, and record the last dose date where the vaccinating clinician will see it.
B-cell-depleting therapy. Rituximab and related agents do not make live vaccines more dangerous by a separate mechanism, but they eliminate the B-cell compartment that would generate a response, so vaccination during profound B-cell depletion may simply fail. Where the patient sits in B-cell recovery is part of the eligibility conversation for both live and inactivated products.
Neither of these is captured by "24 months since transplant, no GVHD, off immunosuppression." Add both to the pre-vaccination check.
5. Making the Plan Auditable
A survivorship care plan only reduces harm if a specific person can act on it, so each item needs an owner and a trigger rather than a category heading.
- Name the responsible clinician for each surveillance task, distinguishing what the transplant program will do at milestone visits from what primary care or a specialist owns between them.
- State the trigger for transplant-team reconsultation in terms the community clinician can apply - a new pulmonary function decline, a new rash, an unexplained cytopenia, a suspected relapse - because the most common failure is a clinician who sees an abnormality and does not know it belongs to the transplant team.
- Reconcile the vaccine record against pre-transplant history and immunization registries, since patients often carry incomplete records across systems and duplicate or missed doses both cause harm.
- Record deferrals with their reason and review date, not merely as blanks. "MMR deferred, active chronic GVHD on systemic therapy, reassess at the next milestone visit" tells the next clinician what changed and what would change it back.
- Address travel explicitly. Yellow fever and other travel vaccines raise live-vaccine questions that arise months later, and patients plan trips without connecting them to their transplant history.
Give the patient a copy in language they use, confirm with teach-back which symptoms warrant an urgent call, and send the plan to the primary and specialty clinicians with permission. A plan that lives only in the transplant chart is not a coordination tool.
A 32-year-old patient is 26 months post-allogeneic HCT, has no acute or chronic GVHD, has been off all immunosuppression for 14 months, and has had no recent IVIG or other antibody-containing product that would interfere with live vaccination. The transplant team confirms immune competence and no product-specific contraindication. What is the most appropriate decision?
A transplant nurse is preparing a comprehensive Survivorship Care Plan (SCP) for an allogeneic HCT survivor transitioning back to their primary care provider at 12 months post-transplant. Which set of components is most essential to include in the SCP to ensure patient safety and continuity of care?